Rehmann Capital Advisory Group Increases Stock Position in Haleon plc (NYSE:HLN)

Rehmann Capital Advisory Group increased its position in shares of Haleon plc (NYSE:HLN) by 25.5% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 13,949 shares of the company’s stock after buying an additional 2,838 shares during the period. Rehmann Capital Advisory Group’s holdings in Haleon were worth $118,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Hexagon Capital Partners LLC boosted its holdings in Haleon by 107.3% during the fourth quarter. Hexagon Capital Partners LLC now owns 4,236 shares of the company’s stock worth $35,000 after buying an additional 2,193 shares in the last quarter. Pinnacle Bancorp Inc. boosted its holdings in Haleon by 853.4% during the fourth quarter. Pinnacle Bancorp Inc. now owns 4,767 shares of the company’s stock worth $39,000 after buying an additional 4,267 shares in the last quarter. Allspring Global Investments Holdings LLC purchased a new position in Haleon during the first quarter valued at $43,000. Tower Research Capital LLC TRC lifted its holdings in Haleon by 146.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,398 shares of the company’s stock valued at $44,000 after purchasing an additional 3,211 shares in the last quarter. Finally, SRS Capital Advisors Inc. lifted its holdings in Haleon by 456.4% during the fourth quarter. SRS Capital Advisors Inc. now owns 5,458 shares of the company’s stock valued at $45,000 after purchasing an additional 4,477 shares in the last quarter. 6.67% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have issued reports on HLN shares. Argus reaffirmed a “buy” rating on shares of Haleon in a report on Tuesday, March 26th. Berenberg Bank started coverage on shares of Haleon in a report on Wednesday, June 5th. They set a “buy” rating on the stock. Finally, HSBC started coverage on shares of Haleon in a report on Wednesday, April 17th. They set a “buy” rating on the stock. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy”.

Haleon Price Performance

Shares of NYSE HLN traded up $0.12 during mid-day trading on Wednesday, reaching $8.73. The company’s stock had a trading volume of 8,889,107 shares, compared to its average volume of 5,298,425. The stock has a 50-day moving average of $8.42 and a two-hundred day moving average of $8.36. The stock has a market capitalization of $39.86 billion, a P/E ratio of 28.72, a P/E/G ratio of 2.25 and a beta of 0.24. The company has a debt-to-equity ratio of 0.53, a quick ratio of 0.73 and a current ratio of 1.04. Haleon plc has a 1-year low of $7.70 and a 1-year high of $8.96.

Haleon (NYSE:HLN) last issued its earnings results on Wednesday, May 1st. The company reported $0.12 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.01. The business had revenue of $3.70 billion during the quarter, compared to analysts’ expectations of $3.71 billion. Haleon had a net margin of 9.68% and a return on equity of 13.17%. On average, equities research analysts anticipate that Haleon plc will post 0.46 EPS for the current fiscal year.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.